The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 1,801–1,900 of 2,716
Kim, S. K., Kim, B. R., Kim, K., Kim, S., Jung, J. H., Hahm, J. R., & Jung, J. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3302 · Cited by 3
“The clinical suspicion is also important in Cushing’s syndrome due to its low specificity of symptoms (16).”
BackgroundKeil, M. F., & Stratakis, C. A. (2013) · Humana Press eBooks · doi:10.1007/978-1-60761-395-4_14 · Cited by 2
“8 m g/dL, further evaluation is necessary [ 17 ] .”
BackgroundMaladie de Cushing à imagerie négative chez l’adulte
Philippon, M., Castinettia, F., & Brue, T. C. (2013) · Annales d Endocrinologie · doi:10.1016/s0003-4266(13)70018-0 · Cited by 3
Ophthalmic manifestations of endocrine disorders: approaches and medical management
Hendrick, A. M., Kahook, M. Y., Daoud, Y. J., & Hazin, R. (2009) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328331903c · Cited by 4
Late-night salivary cortisol (LNSC): data on biological variation
Brescia, V., Zecca, C., Cardinali, R., & Burano, R. (2015) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.1007/s13631-015-0078-2 · Cited by 2
“The measurement of late-night salivary cortisol (LNSC) levels in combination with 1 mg dexamethasone suppression test (DST) and urinary free cortisol (UFC) levels, have been proposed as the first-line laboratory tests in the diagnosis of Cushing’s syndrome (CS) [2].”
MethodExploration biologique de la fonction corticotrope
Fulla, Y., Guignat, L., Dugué, M.-A., Assié, G., & BERTAGNA, X. Y. (2009) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(09)70249-7 · Cited by 13
“[7] Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage”
BackgroundEnfermedad de Cushing en la infancia con presentación atípica
Jiménez, M. J. O., Berdullas, L. P., Fernández, B. H., Gómez, M. R., & Martín, M. B. R. (2012) · Anales de Pediatría · doi:10.1016/j.anpedi.2011.11.025 · Cited by 2
Malik, O., & Westphal, B. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0037 · Cited by 2
“Magiakou et al. 1994; Storr et al. 2007; Nieman et al. 2008; Savage et al. 2008; Pereira et al. 2010”
Restrepo, J. G., Martínez, D. C. C., Hoyos, A. V., et al. (2013) · IATREIA · doi:10.17533/udea.iatreia.14399 · Cited by 2
Störungen der Nebennierenfunktion bei Kindern und Jugendlichen
Partsch, C., & Riepe, F. G. (2015) · Springer eBooks · doi:10.1007/978-3-642-54671-6_90-1 · Cited by 2
Marko, N. F., & Weil, R. J. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511997426.056 · Cited by 2
Hormonal evaluation of adrenal incidentalomas
Loupp, A.-G. L., Cariou, B., Drui, D., Graveline, N., Masson, D., & Bach‐Ngohou, K. (2014) · Annales de biologie clinique · doi:10.1684/abc.2014.1013 · Cited by 2
Nonsuppressible Oral Dexamethasone Suppression Tests but Not Cushing Syndrome
Nair, A., Dhingra, A., Gopi, A., & Jyotsna, V. P. (2016) · Case Reports in Endocrinology · doi:10.1155/2016/3684287 · Cited by 2
“Although some authors have shownmidnight serum cortisol to be highly sensitive and specific for the diagnosis of Cushing syndrome [3], the current clinical practice guidelines of the Endocrine Society suggest one of the four tests with high sensitivity (24 hr urine free cortisol, midnight salivary cortisol, overnight…”
MethodDr. Dhiman, A., & Kar, S. K. (2015) · La Prensa Medica · doi:10.4172/lpma.1000176 · Cited by 2
Matsuzawa, J. S. Y. (2013) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000135 · Cited by 1
Ambroziak, U., Zieliński, G., Toutounchi, S., et al. (2015) · Endokrynologia Polska · doi:10.5603/ep.2015.0011 · Cited by 2
“In such patients, the clinical picture may be more dramatic, suggesting ectopic ACTH secretion [3].”
BackgroundSex Hormone, Pituitary, Parathyroid, and Adrenal Disorders and the Nervous System
Schipper, H. M., Jay, C. A., & Abrams, G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407710-2.00020-5 · Cited by 3
Endocrine Disturbances Affecting Reproduction
Chang, A. Y., & Auchus, R. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4907-4.00023-1 · Cited by 2
The Challenge of Early Diagnosis of Cushing Disease Recurrence!
Bertherat, J. Y. (2016) · Endocrine Practice · doi:10.4158/ep161600.co · Cited by 2
Cushing’s Disease, Refining the Definition of Remission and Recurrence
Ciporen, J. N., Cetas, J. S., McCartney, S., & Fleseriu, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-45950-9_12 · Cited by 2
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2014) · The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy · doi:10.18370/2309-4117.2014.20.22-35 · Cited by 2
Nebenniereninsuffizienz und Nebenniereninzidentalome
Pilz, S. (2017) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-016-0080-2 · Cited by 4
Case Report: Differentiating Obesity from Subclinical Cushing ’s Syndrome
(2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s11-003 · Cited by 2
“Endocrine Society Clinical Practice Guideline for the diagnosis of Cushing’s syndrome do not mention obesity as an indication for screening of adult population (for children indication is decreasing height percentile and increasing weight), and they explicitly recommend against widespread testing [12].”
BackgroundHypothalamic, pituitary and adrenal disorders
Levy, M. J., & Howlett, T. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-5140-1.00018-3 · Cited by 4
Warszawski, L., Esteves, G. S. C., Pagnocelli, A., et al. (2019) · Revista Paulista de Pediatria · doi:10.1590/1984-0462/;2019;37;3;00009 · Cited by 2
Doukhopelnikoff, A., Debrock, G., Steelandt, T., & Jonge, E. T. M. D. (2017) · PubMed Central · Cited by 2
Amar, L., & Azizi, M. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.07.029 · Cited by 2
Primary hyperaldosteronism: difficulties in diagnosis
Shifman, B. M., Platonova, N. M., Nv, M., Troshina, E. A., Sitkin, I. I., Belcevich, D., Дмитриевна, К. Л., Romanova, N. Y., & Kolesnikova, G. S. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.10.000138 · Cited by 2
Cyclical Cushing's syndrome and the presentation of a Bipolar Affective state
Sha, S., Zghoul, T., Wang, Y. Y., et al. (2019) · Bipolar Disorders · doi:10.1111/bdi.12882 · Cited by 2
BERTAGNA, X. Y., Guignat, L., Raux-Demay, M. C., Guilhaume, B., & Girard, F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380926-1.10016-1 · Cited by 5
Suh, J. H., Chao, S. T., & Weil, R. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00027-4 · Cited by 4
Cryptogenic Cushing Syndrome Due to a White Lie
Hesse, R., Seedat, F., Raal, F. J., Snyman, T., & George, J. A. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa035 · Cited by 2
Adrenal Cortical Nodular Hyperplasia
Lotfollahzadeh, S., & Taherian, M. (2020) · StatPearls · Cited by 3
Huckhagel, T., Flitsch, J., Rotermund, R., & Knospe, V. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1200-1528 · Cited by 3
Adenomas hipofisarios funcionantes
Castro, M. A., Corrales, E. P., Ortiz-Flores, A. E., et al. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.001 · Cited by 2
Hormone Excess Syndromes of the Hypothalamic-Pituitary Axis
Agrawal, N., Kim, H. H., Wright, K. E., & Mehta, S. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-030-62187-2_10 · Cited by 3
Disorders of the adrenal cortex
Prescott, P. T. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511920660.034 · Cited by 2
Autonome Kortisolsekretion: Laborartefakt oder Krankheit?
Riester, A., & Beuschlein, F. (2021) · Der Internist · doi:10.1007/s00108-021-01188-6 · Cited by 4
Special Aspects of Cushing’s Syndrome: Cyclic Cushing’s Syndrome
Albiger, N. M. E., & Mantero, F. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-449-4_23 · Cited by 2
Can non-functional adrenal incidentaloma be ranked among cardiovascular risk factors?
Yağız, B., Akalın, A., Yorulmaz, G., Macunluoğlu, A. C., & YAĞIZ, O. (2022) · The European Research Journal · doi:10.18621/eurj.872835 · Cited by 2
“The prevalence of ACS, which is the most common hormonal change in AI, varies due to differences in diagnostic tests and different cut-offs in studies [18].”
BackgroundCapillary microarchitectural changes in Cushing's syndrome
Apaydın, T., Yalçınkaya, Y., Ilgın, C., & Yavuz, D. G. (2022) · Microvascular Research · doi:10.1016/j.mvr.2022.104323 · Cited by 3
Lassandro, N. V., Nicolai, M., Arnaldi, G., Franceschi, A., Pelliccioni, P., Cantini, L., Gesuita, R., Faragalli, A., & Mariotti, C. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05524-2 · Cited by 3
Sherlock, M., & McDonnell, T. (2021) · Medicine · doi:10.1016/j.mpmed.2021.05.011 · Cited by 2
Menstrual Disorders and Hyperandrogenism in Adolescence
DiVall, S. A., & Rosenfield, R. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-73782-9_28 · Cited by 2
Cushing syndrome secondary to a mediastinal carcinoid tumor: a case report
Ershadi, R. E., Vahedi, M., Jahanbin, B., Sarbazzadeh, J., & Rafieian, S. (2022) · International Cancer Conference Journal · doi:10.1007/s13691-022-00542-1 · Cited by 3
“After that, adrenal neoplasms with 20% and ectopic ACTH-releasing tumors with about 10% follow [5, 6].”
BackgroundCushing-szindrómát okozó gyermekkori mellékvesekéreg-adenoma
Bukovszky, B., Gács, Z., Jenővári, Z., Somogyi, D., Micsík, T., Szabó, A., & Sallai, Á. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32358 · Cited by 2
Polycystic Ovarian Syndrome: A Diagnosis of Exclusion
Aubuchon, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_3 · Cited by 3
Wass, J. A. H., Owen, K. R., & Turner, H. E. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199644438.003.0002 · Cited by 2
Ji, D., Zhong, R., & Fan, S. (2022) · BioMed Research International · doi:10.1155/2022/8740408 · Cited by 3
“Steroid hormone measurements and biochemical exclusion of a pheochromocytoma detection and imaging method are often used to screen ACC [8, 9].”
MethodRetractedEthics in Authorship: Considerations and Concerns
Pinho, I., Pinho, J., & Nery, F. (2022) · Acta Médica Portuguesa · doi:10.20344/amp.18646 · Cited by 2
Pediatric Cushing's disease: Case reports and retrospective review
Pomahačová, R., Paterová, P., Nykodýmová, E., Sýkora, J., & Kršek, M. (2022) · Biomedical Papers · doi:10.5507/bp.2022.049 · Cited by 3
ACTH-dependent Cushing's syndrome
Fernandes, S., Varlamov, E. V., & Fleseriu, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00011-x · Cited by 2
Ballerini, M. G., Freire, A. V., Rodríguez, M. E., Valle, S. S., Castro, S., Arcari, A. J., Bergadá, I., & Ropelato, M. G. (2023) · Hormone Research in Paediatrics · doi:10.1159/000530939 · Cited by 4
“Elevated SAF concentration at 11:00 p.m. has high diagnostic accuracy in patients with clinical suspicion of Cushing ’ s syndrome [10, 11].”
BackgroundNew-Onset Sarcoidosis After Remission of Cushing’s Syndrome
Selek, A., Barış, S. A., ÇETİNASLAN, B., Cantürk, Z., Tarkun, İ., & Akyay, Ö. Z. (2016) · Turkish Thoracic Journal · doi:10.5578/ttj.17.1.007 · Cited by 2
Cushing Syndrome: Presentation, Diagnosis, and Treatment, Including Subclinical Cushing Syndrome
Neychev, V. K. (2016) · Springer eBooks · doi:10.1007/978-3-319-44136-8_9 · Cited by 3
Obesity and Metabolic Syndrome: A Phenotype of Mild Long-Term Hypercortisolism?
Wester, V. L., & van Rossum, E. F. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-45950-9_15 · Cited by 2
Наднирникові гіперандрогенії: мультидисциплінарний підхід до вирішення проблеми
Луценко, Л. А. (2017) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.8.80.2016.89535 · Cited by 2
Matta, R. A., Salama, A.-A., El-Hini, S. H., Hamdi, L., Adel, L., & Hassan, H. (2016) · Egyptian Journal of Obesity Diabetes and Endocrinology · doi:10.4103/2356-8062.200908 · Cited by 3
Chrisoulidou, A., Rakitzi, P., Boudina, M., Apostolidou‐Kiouti, F., Poimenidou, E., Papanikolaou, A., Devlioti, A., Rallis, G., & Pazaitou‐Panayiotou, K. (2019) · HORMONES · doi:10.1007/s42000-019-00092-x · Cited by 2
Cushing Disease: Diagnosis and Treatment
Tatsi, C., & Stratakis, C. A. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-11339-1_5 · Cited by 7
III. Diagnosis and Management of Cushing Syndrome and Subclinical Cushing Syndrome
Otsuki, M. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.674 · Cited by 2
Korneeva, Y. A., Bobyreva, N. S., Simonova, N. N., et al. (2019) · Hygiene and Sanitation · doi:10.18821/0016-9900-2019-98-2-159-165 · Cited by 2
Cushing’s disease: Does low-dose pasireotide offer a comparable efficacy and safety to high-dose?
Wong, M., Malabu, U. H., Korah, I., & Tan, Y. (2021) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-20-0206 · Cited by 3
The Diagnosis of Neuroendocrine Neoplasms
Chbat, J., Amer, L. G., Akirov, A., & Ezzat, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-54391-4_2 · Cited by 2
Distinct Late-Night Salivary Cortisol Cut-Off Values for the Diagnosis of Hypercortisolism
van Baal, L., Wichert, M., Zwanziger, D., Dralle, H., Weber, F., Kreitschmann‐Andermahr, I., Führer, D., & Unger, N. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1608-1720 · Cited by 2
Grace, F., Hayes, L. D., & Sculthorpe, N. F. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2223 · Cited by 2
Alerraqi, E. (2016) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000e117 · Cited by 2
The clinical characteristics of pain in patients with pituitary adenomas
Dimopoulou, C., Athanasoulia, A. P., Hanisch, E., Held, S., Toelle, T. R., Sprenger, T., Zieglgänsberger, W., Pfister, H., Roemmler, J., Schopohl, J., et al. (2013) · Endocrine Abstracts · doi:10.1530/endoabs.32.p858 · Cited by 2
Genetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation
Ronchi, C. L., Di, D. G., Sbiera, S., Assié, G., Weigand, I., Calebiro, D., Appenzeller, S., Rubin, B., Waldmann, J., Scaroni, C. M., et al. (2016) · Endocrine Abstracts · doi:10.1530/endoabs.41.oc1.1 · Cited by 3
Molecular Genetics of Cushing Disease
Reincke, M., Theodoropoulou, M., & Albani, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64339-8 · Cited by 2
SIMBA: Using Kolb’s Learning Theory in Simulation-Based Learning to Improve Participants' ConfidencePreprint
Davitadze, M., Ooi, E., Ng, C. Y., Zhou, D., Thomas, L., Hanania, T., Blaggan, P., Evans, N., Chen, W., Melson, E., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-127549/v1 · Cited by 2
PRKAR1A-negative familial Cushing’s syndrome: two case reports
Lim, L., Kitan, N., Paramasivam, S. S., Ratnasingam, J., Ibrahim, L., Chan, S. P., Tan, A. T. B., & Vethakkan, S. R. (2015) · Journal of Medical Case Reports · doi:10.1186/s13256-015-0757-7 · Cited by 1
“4) [3, 4].”
Incidentally Discovered Aldosterone and Cortisol Cosecreting Adrenal Cortical Adenoma
Bae, J. Y., Lee, J., Han, Y., Min, S. K., Cho, M.-S., & Sung, Y. (2015) · Ewha Medical Journal · doi:10.12771/emj.2015.38.3.129 · Cited by 1
“8 μg/dL cutoff to rule out Cushing syndrome based on the current Endocrine Society guidelines [5].”
MethodMEN 2A with double mutation in RET gene: Ectopic ACTH production in medullary thyroid carcinoma
Ares, J., Díaz-Naya, L., Martín-Nieto, A., et al. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.06.025 · Cited by 1
ACTH measurements in Cushing's syndrome: the need for caution and communication
Qian, S. Y., Smith, J. D., Wijeratne, N. G., & Kevat, D. (2019) · Pathology · doi:10.1016/j.pathol.2019.08.007 · Cited by 1
Inoue, S., Hayashi, T., Teishima, J., & Matsubara, A. (2020) · Urologia Internationalis · doi:10.1159/000508765 · Cited by 1
Nascimento, G. C., Nascimento, A. G., Parente, C. D. M. R. V., Rodrigues, V. P., Azulay, R. S. D. S., Rocha, V. C. D. C., Damianse, S. D. S. P., Magalhães, M., Faria, M. D. S., & Gomes, M. B. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01357-8 · Cited by 2
Durankus, N. K., Samancı, Y., Yılmaz, M., Şengöz, M., Bölükbaşı, Y., & Peker, S. (2022) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.20.05048-1 · Cited by 1
Modern principles of the diagnosis and conservative treatment of Cushing disease
Abdali, A., Astaf’Eva, L. E., Kalinin, P. L., Trunin, Y., Chernov, I. V., Chmutin, G. E., Abdali, B., Sherzad, G., & Simfukwe, K. (2020) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2010-08 · Cited by 1
Endocrine Disorders and the Cardiovascular System
Ghaemmaghami, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00001-6 · Cited by 7
Elliott, W. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47871-7.00074-5 · Cited by 1
Takiguchi, M. K., Morimoto, S., Watanabe, D., Abe, K., & Ichihara, A. (2022) · Hypertension Research · doi:10.1038/s41440-022-00939-8 · Cited by 2
“secretion by one spot urine data point due to the circadian rhythm of cortisol secretion [1].”
BackgroundMethodInfluentialPikunov, M. Y., Савельева, Т. В., Белая, Ж. Е., Алексеевна, Б. С., & Дегтярев, М. В. (2022) · Хирургия Восточная Европа · doi:10.34883/pi.2022.11.2.004 · Cited by 1
ÜNSAL, Y. A., Gül, Ö. Ö., Ateş, C., Aydemir, E., Cander, S., Ersoy, C., Özpar, R., Hakyemez, B., & Ertürk, E. (2022) · The Neuroradiology Journal · doi:10.1177/19714009221126016 · Cited by 1
“7% in the literature.(22,23) Some factors are associated with a lower accuracy rate in lateralization-like anomalous petrosal sinus anatomy and catheter positioning.”
BackgroundCastro, M. A., Mariño‐Sánchez, F., Fernández, A. G., Cancela, A. A., & Berrocal, V. R. (2022) · Neurocirugía (English Edition) · doi:10.1016/j.neucie.2021.07.002 · Cited by 3
Presurgical predictive factors of surgical remission in Cushing's disease. Study of 32 cases
Castro, M. A., Pinedo, M. M., Fernández-Argüeso, M., Pérez, M. P., Ruiz, E. B., Pian, H. G., Berrocal, V. R., & Corrales, E. P. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.07.003 · Cited by 3
Diagnostic Evaluation of Pediatric Hypertension
Larkins, N., & Roebuck, D. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-06231-5_32 · Cited by 2
FAF1 Gene Involvement in Pituitary Corticotroph Tumors
Nguyen, M. H., Maria, A. G., Faucz, F. R., Trivellin, G., Stratakis, C. A., & Tatsi, C. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2192-1761 · Cited by 1
“The diagnosis of CD was based on previously described criteria [8, 9].”
How an appreciation of dynamics has altered our understanding of the HPA axis
Lightman, S. L., & Upton, T. J. (2024) · Stress · doi:10.1080/10253890.2023.2297371 · Cited by 2
“Most importantly, this data will serve as potential reference range for comparison with disease states, in particular endocrine disorders such as Cushing’s (Nieman et al., 2008) and primary aldosteronism (Funder et al., 2016), where disturbance of normal hormonal rhythmicity is a pathogenic feature.”
From Knee Pain Consultation to Pituitary Surgery: The Challenge of Cushing Disease Diagnosis
Gómez-Gutiérrez, M., Cañas, J. M. H., & Ossa, A. B. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae048 · Cited by 3
“An early hallmark of endogenous CS is the disruption of physiological circadian cortisol patterns, characterized by a constant cortisol level throughout the day or no significant decrease [2].”
BackgroundInfluentialDie aktuelle Guideline Nebenniereninzidentalom
Braun, L. (2024) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-024-00242-6 · Cited by 1
Blood DNA methylation of CRF and its association with amygdala volume and mood in Cushing’s syndrome
Lee, R. S., Vives, A. S., Garrison‐Desany, H. M., Aulinas, A., Carey, J. L., Vives‐Gilabert, Y., Cox, O., Cuilan, G., Webb, S. M., & Resmini, E. (2024) · Frontiers in Epigenetics and Epigenomics · doi:10.3389/freae.2024.1435634 · Cited by 1
Agrawal, N., Sarkar, D., Chatterjee, S., Sinha, P., Bhattacharya, R., Ranjan, P., Chakraborty, P. P., & Bhattacharjee, R. (2024) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715241293817 · Cited by 1
Mineralocorticoid Effects in Cushing’s Disease: A Case Report
Pereira, V. R., Silva, B. C., Castanheira, D., Ferreira, G., & de Almeida, R. S. (2024) · Cureus · doi:10.7759/cureus.75780 · Cited by 2
Cao, G., Huang, J., Lin, Q., Wang, R., Wu, M., Chen, C., Yiu, K., & Yiu, K.-H. (2025) · Journal of Clinical Hypertension · doi:10.1111/jch.14979 · Cited by 1
Evaluation of the Adrenal Mass in Urologic Practice
Schmidt, J., & Strother, M. C. (2025) · Urologic Clinics of North America · doi:10.1016/j.ucl.2025.01.011 · Cited by 1
McNicoll, M., Himdi, L., Tewfik, M. A., et al. (2025) · SAGE Open Medical Case Reports · doi:10.1177/2050313x251332081 · Cited by 1
Baruah, M. M., Adhikari, U., Prasad, T. N., et al. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_291_24 · Cited by 1
Secondary Hypertension in Children—Identifying and Investigating at Risk Children
Ding, F. C. L., & Sandery, B. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01333-8 · Cited by 1
“Initial screening test for Cushing syndrome include 24 h urinary free cortisol, low dose dexamethasone-suppression test, or late-night salivary or serum cortisol [69].”
Anaesthetic considerations for adrenalectomy: A clinical communication
Pandey, S., & Sarvesh, A. (2025) · Southeast Asian Journal of Health Professional · doi:10.18231/j.sajhp.2025.010 · Cited by 1
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.